Moleculin Biotech, Inc. (MBRX) Stock Price

MBRXStock
$0.6195.71%52W
Market Cap$11.90M
P/E
PEG Ratio
Div yield
Beta1.98

MBRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-98.58%
Price vs S&P 500 (4W)-75.23%
VGM Score10.46

MBRX Earnings Surprise History

Q2 25-12.25est. -10.08
Q3 25-0.68est. -6.58
Q1 26-3.54est. -1.66
Q2 26-1.40est. -1.55

MBRX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.11
4.11
4.11

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
MBRXMoleculin Biotech, Inc.
F$0.61
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Moleculin Biotech, Inc.

Moleculin Biotech is a clinical-stage biopharmaceutical company developing a portfolio of drug candidates for resistant cancers and viral infections. The company's lead program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance while reducing cardiotoxic side effects.